A Phase 2 interventional study of Brivaracetam in Epilepsy, sponsored by UCB Pharma. Completed at 39 sites in 6 countries. Open to participants aged 1 Month to 16 Years. Per ClinicalTrials.gov, last updated 2018-07-11.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.
Among the 34 studies testing brivaracetam in Epilepsy, this one is the 17th largest by enrollment, is one of 4 that started in 2011, is one of 6 in phase 2, and was the 6th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Belgium, Czechia and 8 more countries
Ages 1 mo+
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 1 Month to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2011.
This study's enrollment of 100 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 34 interventional studies. Of the 31 that completed or were terminated, 23 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 59th largest by enrollment of the 116 interventional ones that give a count, is one of 13 that started in 2011, is one of 26 in phase 2, and was the 30th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing brivaracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Initial study in children with epilepsy to evaluate the pharmacokinetics, safety, tolerability and preliminary efficacy of adjunctive treatment with brivaracetam, and to develop dosing adaptations for future studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Brivaracetam
Oral solution Evaluation period (3 weeks up-titration): For subjects ≥8 years: * \~0.4 mg/kg bid for Week 1 * \~0.8 mg/kg bid for Week 2 * \~1.6 mg/kg bid for Week 3 For subjects \<8 years: * \~0.5 mg/kg bid for Week 1 * \~1.0 mg/kg bid for Week 2 * \~2.0 mg/kg bid for Week 3 Down-titration period (up to 2 weeks): For subjects ≥8 years: * \~0.8 mg/kg bid for Week 4 * \~0.4 mg/kg bid for Week 5 For subjects \<8 years: * \~1.0 mg/kg bid for Week 4 * \~0.5 mg/kg bid for Week 5
Mean Trough Plasma Concentration at 3rd Level for Age Range ≥1 Month to <2 Years
Time frame: Day 21
Mean Trough Plasma Concentration at 3rd Level for Age Range ≥2 to <12 Years
Time frame: Day 21
Mean Trough Plasma Concentration at 3rd Level for Age Range ≥12 to <16 Years
Time frame: Day 21
Mean Max Plasma Concentration for Age Range ≥1 Month to <2 Years
Time frame: Day 21
Mean Max Plasma Concentration for Age Range ≥2 to <12 Years
Time frame: Day 21
Mean Max Plasma Concentration for Age Range ≥12 to <16 Years
Time frame: Day 21
Number of Subjects With at Least One Treatment-emergent Adverse Event Reported During the 3-week Evaluation Period
Time frame: Baseline to end of the 3-week evaluation period
Number of Subjects With a 50 % Reduction in Seizures Based on Seizure Diary Data From Baseline to End of the 3-week Evaluation Period
Time frame: Baseline to end of the 3-week evaluation period
Percent Compliance With Brivaracetam Oral Solution During the 3-week Evaluation Period
Time frame: Baseline to the end of the 3-week evaluation period
The N01263 study began recruitment in July 2011, with subjects enrolled in the European Union, Mexico, and the United States. The study concluded in March 2013.
| Milestone | Brivaracetam (ES) |
|---|---|
| Started | 100 |
| Completed | 90 |
| Not completed | 10 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Sae, non-fatal | 1 |
| Withdrew: Ae, non-serious non-fatal | 5 |
| ug/mL | Brivaracetam (PPS) |
|---|---|
| Mean Trough Plasma Concentration at 3rd Level for Age Range ≥1 Month to <2 Years | 0.825 ± 0.826 |
| ug/mL | Brivaracetam (PPS) |
|---|---|
| Mean Trough Plasma Concentration at 3rd Level for Age Range ≥2 to <12 Years | 0.967 ± 0.536 |
| ug/mL | Brivaracetam (PPS) |
|---|---|
| Mean Trough Plasma Concentration at 3rd Level for Age Range ≥12 to <16 Years | 1.117 ± 0.400 |
| ug/mL | Brivaracetam (PPS) |
|---|---|
| Mean Max Plasma Concentration for Age Range ≥1 Month to <2 Years | 2.071 (0.320 to 4.305) |
| ug/mL | Brivaracetam (PPS) |
|---|---|
| Mean Max Plasma Concentration for Age Range ≥2 to <12 Years | 2.673 (0.561 to 5.418) |
| ug/mL | Brivaracetam (PPS) |
|---|---|
| Mean Max Plasma Concentration for Age Range ≥12 to <16 Years | 2.861 (2.627 to 3.371) |
| participants | Brivaracetam (SS) |
|---|---|
| Number of Subjects With at Least One Treatment-emergent Adverse Event Reported During the 3-week Evaluation Period | 66 |
| participants | Brivaracetam (FAS) |
|---|---|
| Number of Subjects With a 50 % Reduction in Seizures Based on Seizure Diary Data From Baseline to End of the 3-week Evaluation Period | 17 |
| participants | Brivaracetam (SS) |
|---|---|
| <80 % | 5 |
| 80 % to 120 % | 90 |
| >120 % | 2 |
Collected over Treatment-emergent Adverse Events (TEAEs) were collected during the course of the study up to day 49.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brivaracetam (SS) | — | 8/99 (8.1%) | 33/99 (33.3%) |
| Event | Brivaracetam (SS) |
|---|---|
| ConvulsionNervous system disorders | 4/99 |
| DehydrationMetabolism and nutrition disorders | 2/99 |
| DiarrhoeaGastrointestinal disorders | 1/99 |
| PyrexiaGeneral disorders | 1/99 |
| Otitis mediaInfections and infestations | 1/99 |
| Respiratory tract infectionInfections and infestations | 1/99 |
| ToxoplasmosisInfections and infestations | 1/99 |
| Cytomegalovirus test positiveInvestigations | 1/99 |
| Event | Brivaracetam (SS) |
|---|---|
| IrritabilityGeneral disorders | 8/99 |
| SomnolenceNervous system disorders | 8/99 |
| PyrexiaGeneral disorders | 7/99 |
| Decreased appetiteMetabolism and nutrition disorders | 7/99 |
| ConvulsionNervous system disorders | 6/99 |
| FatigueGeneral disorders | 5/99 |
| PharyngotonsillitisInfections and infestations | 5/99 |
Baseline Characteristics consists of the Enrolled Subjects analysis set, which is comprised of all subjects enrolled into the study.
| Age, Continuous(years) | Brivaracetam (ES) |
|---|---|
| Mean | 6.3 ± 4.8 |
| Sex: Female, Male(Participants) | Brivaracetam (ES) |
|---|---|
| Female | 51 |
| Male | 49 |
| Weight(kilograms) | Brivaracetam (ES) |
|---|---|
| Mean | 24.2 ± 16.2 |
| Height(centimeters) | Brivaracetam (ES) |
|---|---|
| Mean | 111.8 ± 32.9 |
| BMI(kg/m^2) | Brivaracetam (ES) |
|---|---|
| Median | 17.1 ± 3.4 |
| Racial Group(participants) | Brivaracetam (ES) |
|---|---|
| Black or African American | 4 |
| White | 80 |
| Other | 16 |
The record gives a start of Jul 2011, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 3 years 10 months after primary completion. A results delay was requested in Mar 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam